Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. This is due to its aggressive course, late diagnosis and its intrinsic drugs resistance. The complexity of the tumor, in terms of cell components and heterogeneity, has led to the approval of few therapies with limited efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Agostini, Antonio, Guerriero, Ilaria, Piro, Geny, Quero, Giuseppe, Roberto, Luca, Esposito, Annachiara, Caggiano, Alessia, Priori, Lorenzo, Scaglione, Giulia, De Sanctis, Francesco, Sistigu, Antonella, Musella, Martina, Larghi, Alberto, Rizzatti, Gianenrico, Lucchetti, Donatella, Alfieri, Sergio, Sgambato, Alessandro, Bria, Emilio, Bizzozero, Laura, Arena, Sabrina, Ugel, Stefano, Corbo, Vincenzo, Tortora, Giampaolo, Carbone, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668479/
https://www.ncbi.nlm.nih.gov/pubmed/37996891
http://dx.doi.org/10.1186/s12967-023-04733-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668479/
https://www.ncbi.nlm.nih.gov/pubmed/37996891
http://dx.doi.org/10.1186/s12967-023-04733-z

Ejemplares similares